Tizona Therapeutics
2014
FOUNDED
PRIVATE
STATUS
21-30
EMPLOYEES
Series B3
LATEST DEAL TYPE
$15M
LATEST DEAL AMOUNT
9
INVESTORS
Description
Developer of cancer immunotherapy treatments designed to harness the power of the immune system to develop treatments for cancer and autoimmune diseases. The company's treatments are designed to modulate the activity of immunosuppressive cells by targeting the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, enabling cancer patients to achieve complete, durable remissions and help patients to live longer.
Website
Formerly Known As
Vesuvius Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 4000 Shoreline Court
- Suite 200
- South San Francisco, CA 94080
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Tizona Therapeutics’s full profile, request a free trial.
Tizona Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Early Stage VC (Series B3) | 10-Jan-2019 | $15M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 6. Corporate | 03-Jan-2019 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 | |
| 5. Debt - General | 06-Sep-2018 | 0000 | 00000 | Completed | Pre-Clinical Trials | |
| 4. Early Stage VC (Series B2) | 04-Aug-2017 | 0000 | 0000 | 0000 | Completed | Pre-Clinical Trials |
| 3. Early Stage VC (Series B) | 23-Feb-2016 | 0000 | 0000 | 000.00 | Completed | Pre-Clinical Trials |
| 2. Early Stage VC (Series A) | 17-Sep-2015 | $27M | $27M | 0000 | Completed | Startup |
| 1. Accelerator/Incubator | 31-Jul-2015 | Completed | Startup |
Tizona Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B3 | 0,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series B2 | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series B | 13,333,332 | $0.000100 | $0.01 | $1.5 | $1.5 | 1x | $1.5 | 13.33% |
| Series A | 27,217,500 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 27.22% |
Tizona Therapeutics Competitors (48)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immatics | Venture Capital-Backed | Tübingen, Germany | 00 | 00000 | 00000000000 | 00000 |
| 000000000 | Venture Capital-Backed | Rockville, MD | 000.00 | 0000000000 0 | 000.00 | |
| 000 000000000000 | Formerly VC-backed | Boston, MA | 0000 | 000000&0 | 0000 | |
| 00000000000 | Angel-Backed | Culver City, CA | 00000 | 000000000000 | 00000 | |
| 00000000 | Formerly VC-backed | Munich, Germany | 000.00 | 000000&0 | 000.00 |
Tizona Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| AbbVie | Corporation | Minority | 000 0000 | 000000 0 | ||
| Abingworth Management | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Canaan Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Lightstone Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Amgen Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Tizona Therapeutics Executive Team (21)
8 Former Executives
You’re viewing 5 of 21 executives. Get the full list »Tizona Therapeutics Board Members (13)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Daniel Hicklin Ph.D | MPM Capital | Board Member | 000 0000 | |
| KT Moortgat Ph.D | Self | Board Member | 000 0000 | |
| Luke Evnin Ph.D | MPM Capital | Chairman | 000 0000 | |
| Nina Kjellson | Canaan Partners | Board Member | 000 0000 | |
| Pablo Cagnoni MD | MPM Capital | Board Member | 000 0000 |
6 Former Board Members
You’re viewing 5 of 13 board members. Get the full list »